Lake Street Advisors Group LLC Increases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Lake Street Advisors Group LLC boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 7.4% in the third quarter, Holdings Channel reports. The fund owned 2,250 shares of the medical research company’s stock after buying an additional 156 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Natera were worth $286,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Park Avenue Securities LLC boosted its stake in shares of Natera by 17.5% in the first quarter. Park Avenue Securities LLC now owns 5,368 shares of the medical research company’s stock valued at $491,000 after purchasing an additional 799 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Natera by 25.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock valued at $528,000 after acquiring an additional 1,155 shares in the last quarter. LVW Advisors LLC purchased a new stake in shares of Natera during the first quarter worth about $209,000. Allspring Global Investments Holdings LLC lifted its stake in shares of Natera by 19.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after acquiring an additional 143,246 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Natera in the first quarter worth about $33,956,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 691 shares of the company’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $118.81, for a total value of $82,097.71. Following the completion of the sale, the chief financial officer now owns 72,709 shares of the company’s stock, valued at $8,638,556.29. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now directly owns 206,400 shares in the company, valued at approximately $21,211,728. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 691 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $118.81, for a total value of $82,097.71. Following the completion of the sale, the chief financial officer now owns 72,709 shares of the company’s stock, valued at approximately $8,638,556.29. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,149 shares of company stock valued at $6,007,018. 7.60% of the stock is currently owned by corporate insiders.

Natera Trading Down 1.3 %

Shares of NASDAQ:NTRA opened at $117.67 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company’s 50-day moving average price is $123.24 and its 200 day moving average price is $111.34. The company has a market cap of $14.55 billion, a PE ratio of -48.03 and a beta of 1.53. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $133.54.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The business’s revenue was up 58.1% on a year-over-year basis. Sell-side analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NTRA shares. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Morgan Stanley raised their price objective on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Stephens reissued an “overweight” rating and issued a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $150.00 target price on shares of Natera in a report on Friday, September 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.44.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.